The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
 
Masatoshi Kudo
Honoraria - Abbvie; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; MSD; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Kenta Motomura
Honoraria - Eisai; Eisai
 
Yoshiyuki Wada
No Relationships to Disclose
 
Yoshitaka Inaba
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; Eisai; Guerbet
Research Funding - AstraZeneca (Inst); Pfizer (Inst); Takeda (Inst)
 
Yasunari Sakamoto
Research Funding - Ono Pharmaceutical (Inst); Sumitomo Dainippon (Inst); Takeda (Inst)
 
Masayuki Kurosaki
Speakers' Bureau - Abbvie; Bayer; Eisai; Gilead Sciences
 
Yoshiko Umeyama
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yoichi Kamei
Employment - Pfizer
 
Junichiro Yoshimitsu
Employment - Pfizer
 
Yosuke Fujii
Employment - Pfizer
 
Mana Aizawa
Employment - Pfizer
 
Paul B. Robbins
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)